Neurofilamentopathy in neurodegenerative diseases

Open Neurology Journal

Volumn 5, Issue 1, 2011, Pages 58-62

  Liu, Quan ^a   Xie, Fang ^b   Alvarado Diaz, Abdiel ^c   Smith, Mark A ^d   Moreira, Paula I ^e   Zhu, Xiongwei ^d   Perry, George ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f University of San Antonio   (United States)

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Glycosylation; Neurofilament; Oxidation; Parkinson disease; Phosphorylation

Indexed keywords

DYNEIN ADENOSINE TRIPHOSPHATASE; NEUROFILAMENT PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CODON; DEGENERATIVE DISEASE; DNA MODIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; NEUROFIBRILLARY TANGLE; NEUROFILAMENT; NONHUMAN; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 80053515856     PISSN: None     EISSN: 1874205X     Source Type: Journal    
DOI: 10.2174/1874205X01105010058     Document Type: Review

References (70)

1. Liu Q, Xie F, Siedlak SL, et al. Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 2004; 61: 3057-75.
2. Al-Chalabi A, Miller CC. Neurofilaments and neurological disease. Bioessays 2003; 25: 346-55.
3. Zhu Q, Lindenbaum M, Levavasseur F, Jacomy H, Julien JP. Disruption of the NF-H gene increases axonal microtubule content and velocity of neurofilament transport: relief of axonopathy resulting from the toxin beta, beta¢-iminodipropionitrile. J Cell Biol 1998; 143: 183-93.
4. Dong DL, Xu ZS, Chevrier MR, Cotter RJ, Cleveland DW, Hart GW. Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetyl-glucosamine moieties on neurofilament polypeptides L and M. J Biol Chem 1993; 268: 16679-87.
5. Manetto V, Sternberger NH, Perry G, Sternberger LA, Gambetti P. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988; 47: 642-53.
6. Leigh PN, Dodson A, Swash M, Brion JP, Anderton BH. Cytoskeletal abnormalities in motor neuron disease. An immunocytochemical study. Brain 1989; 112: 521-35.
7. Murayama S, Bouldin TW, Suzuki K. Immuno-cytochemical and ultrastructural studies of upper motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol 1992; 83: 518-24.
8. Bergeron C, Beric-Maskarel K, Muntasser S, Weyer L, Somerville MJ, Percy ME. Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons. J Neuropathol Exp Neurol 1994; 53: 221-30.
9. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993; 73: 23-33.
10. Wong PC, Marszalek J, Crawford TO, et al. Increasing neurofilament subunit NF-M expression reduces axonal NF-H, inhibits radial growth, and results in neurofilamentous accumulation in motor neurons. J Cell Biol 1995; 130: 1413-22.
11. Cote F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993; 73: 35-46.
12. [Meier J, Couillard-Despres S, Jacomy H, Gravel C, Julien JP. Extra neurofilament NF-L subunits rescue motor neuron disease caused by overexpression of the human NF-H gene in mice. J Neuropathol Exp Neurol 1999; 58: 1099-110.
13. Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J. Neuropathol Exp Neurol 2000; 59: 972-82.
14. Menzies FM, Grierson AJ, Cookson MR, et al. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J Neurochem 2002; 82: 1118-28.
15. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 1757-61.
16. Tomkins J, Usher P, Slade JY, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998; 9: 3967-70.
17. Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-64.
18. Lobsiger CS, Garcia ML, Ward CM, Cleveland DW. Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci USA 2005; 102: 10351-6.
19. Ludemann N, Clement A, Hans VH, Leschik J, Behl C, Brandt R. O-glycosylation of the tail domain of neurofilament protein M in human neurons and in spinal cord tissue of a rat model of amyotrophic lateral sclerosis (ALS). J Biol Chem 2005; 280: 31648-58.
20. Kesavapany S, Patel V, Zheng YL, et al. Inhibition of Pin1 reduces glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. Mol Biol Cell 2007; 18: 3645-55.
21. Teuling E, van Dis B, Wulf PS, et al. A novel mouse model with impaired dynein/dynactin function develops amyotrophis lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice. Hum Mol Genet 2008; 17: 2849-62.
22. Cheroni C, Marino M, Tortarolo M, et al. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet 2009; 18: 82-96.
23. Volkening K, Leystra-Lantz C, Yang W, Jaffee H, Strong MJ. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res 2009; 1305: 168-82.
24. Williamson TL, Bruijn LI, Zhu Q, et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosislinked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA 1998; 95: 9631-6.
25. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006; 66: 852-6.
26. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010; 220: 114-9.
27. Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc Natl Acad Sci USA 1985; 82: 3916-20.
28. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 1987; 84: 3033-6.
29. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000; 275: 5535-44.
30. Trojanowski JQ, Mawal-Dewan M, Schmidt ML, Martin J, Lee VM. Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Res 1993; 618: 333-7.
31. Maccioni RB, Otth C, Concha II, Munoz JP. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 2001; 268: 1518-27.
32. Mandelkow EM, Drewes G, Biernat J, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992; 314: 315-21.
33. McLachlan DR, Lukiw WJ, Wong L, Bergeron C, Bech-Hansen NT. Selective messenger RNA reduction in Alzheimer's disease. Brain Res 1988; 427: 255-61.
34. Wataya T, Nunomura A, Smith MA, et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002; 277: 4644-8.
35. Liu Q, Raina AK, Smith MA, Sayre LM, Perry G. Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Mol Aspects Med 2003; 24: 305-13.
36. Pamplona R, Dalfo E, Ayala V, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 2005; 280: 21522-30.
37. Liao L, Cheng D, Wang J, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 2004; 279: 37061-8.
38. Deng Y, Li B, Liu F, et al. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J 2008; 22: 138-45.
39. Bjorkdahl C, Sjögren MK, Zhou X, et al. Small heat shock proteins Hsp27 or alphaB-crystallin and the protein components of neurofibrillary tangles: tau and neurofilaments. J Neurosci Res 2008; 86: 1343-52.
40. Mayeux R, Honig LS, Tang MX, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61: 1185-90.
41. Lee HG, Perry G, Moreira PI, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-9.
42. Thangavel R, Sahu SK, Van Hoesen GW, Zaheer A. Loss of nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in Alzheimer's disease. Neuroscience 2009; 160: 427-33.
43. Yang X, Yang Y, Lou Y, Li G, Wang J, Yang ES. Hyperphosphorylation and accumulation of neurofilament proteins in transgenic mice with Alzheimer presenilin 1 mutation. Cell Mol Neurobiol 2009; 29: 497-501.
44. Ahlijanian MK, Barrezueta NX, Williams RD, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 2000; 97: 2910-5.
45. Sonoda Y, Mukai H, Matsuo K, et al. Accumulation of tumorsuppressor PTEN in Alzheimer neurofibrillary tangles. Neurosci Lett 1996; 471: 20-4.
46. Galloway PG, Mulvihill P, Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992; 140: 809-22.
47. Trimmer PA, Borland MK, Keeney PM, Bennett JP Jr, Parker WD Jr. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem 2004; 88: 800-12.
48. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999; 8: 567-74.
49. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 1998; 103: 424-7.
50. Lucking CB, Durr A, Bonifati V, et al. Association between earlyonset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000; 342: 1560-7.
51. Lim KL, Dawson VL, Dawson TM. The genetics of Parkinson's disease. Curr Neurol Neurosci Rep 2002; 2: 439-46.
52. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004; 4: 3943-52.
53. Hill WD, Arai M, Cohen JA, Trojanowski JQ. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. J Comp Neurol 1993; 329: 328-36.
54. Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci Lett 2002; 322: 57-61.
55. Perez-Olle R, Lopez-Toledano MA, Goryunov D, et al. Mutations in the neurofilament light gene linked to Charcot-Marie-Tooth disease cause defects in transport. J Neurochem 2005; 93: 861-74.
56. Kruger R, Fischer C, Schulte T, et al. Mutation analysis of the neurofilament M gene in Parkinson's disease. Neurosci Lett 2003; 351: 125-9.
57. Han F, Bulman DE, Panisset M, Grimes DA. Neurofilament M gene in a French-Canadian population with Parkinson's disease. Can J Neurol Sci 2005; 32: 68-70.
58. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007; 28: 742-7.
59. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994; 13: 975-88.
60. Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67: 37-46.
61. Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou K. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 2002; 4: 93-6.
62. Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126: 590-7.
63. Zuchner S, Vorgerd M, Sindern E, Schroder JM. The novel neurofilament light (NEFL) mutation Glu397Lys is associated with a clinically and morphologically heterogeneous type of Charcot-Marie-Tooth neuropathy. Neuromuscul Disord 2004; 14: 147-57.
64. Yoshihara T, Yamamoto M, Hattori N, et al. Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. J Peripher Nerv Syst 2002; 7: 221-4.
65. Sasaki T, Gotow T, Shiozaki M, et al. Aggregate formation and phosphorylation of neurofilament-L Pro22 Charcot-Marie-Tooth disease mutants. Hum Mol Genet 2006; 15: 943-52.
66. Perez-Olle R, Lopez-Toledano MA, Liem RK. The G336S variant in the human neurofilament-M gene does not affect its assembly or distribution: importance of the functional analysis of neurofilament variants. J Neuropathol Exp Neurol 2004; 63: 759-74.
67. Zhai J, Lin H, Julien JP, Schlaepfer WW. Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. Hum Mol Genet 2007; 16: 3103-16.
68. Hull E, Spoja C, Cordova M, Cohlberg JA. Neurofilament protein aggregation in a cell line model system. Biochem Biophys Res Commun 2008; 366: 73-9.
69. Zhu X, Liu Y, Yin Y, et al. MSC p43 required for axonal development in motor neurons. Proc Natl Acad Sci USA 2009; 106: 15944-9.
70. Dequen F, Filali M, Larivière RC, Perrot R, Hisinaga S, Julien J. Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E. Hum Mol Genet 2010; 19: 2616-29.